Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BIPHETAMINE 12.5 vs BIPHETAMINE 7.5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Biphetamine 12.5 is a central nervous system stimulant that increases the levels of norepinephrine and dopamine in the synaptic cleft by inhibiting the reuptake of these neurotransmitters and by promoting their release from presynaptic terminals.
Biphetamine 7.5 is a combination of amphetamine enantiomers (dextroamphetamine and levoamphetamine) that increase synaptic concentrations of dopamine and norepinephrine by inhibiting presynaptic reuptake and promoting release into the synaptic cleft.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Attention deficit hyperactivity disorder (ADHD),Narcolepsy
12.5 mg orally once daily in the morning, may titrate weekly by 12.5 mg to maximum 75 mg/day.
Initial 7.5 mg orally once daily in the morning, titrated based on response and tolerability. Maximum daily dose is 30 mg.
9-14 hours in children and adolescents; clinical effects typically last 4-6 hours due to distribution and tolerance. Terminal half-life may be longer in adults with higher body fat (up to 20 hours).
6-8 hours (amphetamine moiety), 10-13 hours (dextroamphetamine); clinical effects may outlast serum levels due to accumulation.
Hepatic metabolism via CYP2D6 and other pathways; primarily deamination and oxidation.
Hepatic metabolism via CYP2D6, deamination, and glucuronidation; major metabolites include 4-hydroxyamphetamine and hippuric acid.
Renal: 70-80% as unchanged drug and metabolites (primarily deaminated metabolites); fecaroute is negligible. Urinary p H-dependent: acidification increases renal clearance, alkalinization decreases it.
Renal: ~70-90% unchanged and as active metabolites; minor fecal elimination. Acidic urine (p H <5.6) increases excretion; alkaline urine (p H >7.0) decreases it.
20-40%, primarily to albumin and alpha-1 acid glycoprotein.
~16-20%; primarily albumin and alpha-1-acid glycoprotein.
3.2-5.6 L/kg, indicating extensive tissue distribution; crosses blood-brain barrier readily.
4-5 L/kg; extensive tissue distribution with high CNS penetration.
Oral: 75-100% (amphetamines have high and consistent oral bioavailability).
PO: 75-100% (immediate-release); food delays absorption but does not affect total AUC.
GFR <30 m L/min: avoid use; GFR 30-60 m L/min: reduce dose by 50% and monitor; GFR >60 m L/min: no adjustment.
GFR 15-29 m L/min: 50% of normal dose; GFR <15 m L/min: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
6-12 years: 6.25 mg or 12.5 mg once daily in the morning, may increase by 6.25 mg weekly up to 37.5 mg/day; weight-based: 0.3-0.8 mg/kg/day, max 37.5 mg/day.
Children 6-17 years: initial 2.5 mg orally once daily; may increase by 2.5-5 mg weekly; maximum 30 mg daily.
Initiate at 6.25 mg once daily in the morning, increase cautiously by 6.25 mg weekly; monitor for cardiovascular and psychiatric effects; maximum daily dose 37.5 mg.
Start at 2.5 mg orally once daily; increase by 2.5 mg weekly as tolerated; monitor for cardiovascular effects and insomnia.
Biphetamine has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular events.
WARNING: ABUSE AND DEPENDENCE. Amphetamines have a high potential for abuse; prolonged use may lead to drug dependence; misuse may cause sudden death or serious cardiovascular events.
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems,Risk of hypertension and tachycardia,Risk of psychiatric adverse events such as exacerbation of pre-existing psychosis, mania, or aggression,Risk of seizures in patients with a history of seizures,Long-term suppression of growth in children
Serious cardiovascular events: sudden death, stroke, myocardial infarction in patients with structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase may occur; monitor for hypertension and tachycardia.,Psychiatric adverse reactions: exacerbation of pre-existing psychosis, mania, aggression, or new psychotic/manic symptoms.,Long-term suppression of growth in children; monitor height and weight.,Seizures: may lower seizure threshold; discontinue if seizures occur.,Peripheral vasculopathy: Raynaud's phenomenon; monitor for digital changes.
History of drug abuse,Cardiovascular disease including symptomatic cardiovascular disease, advanced arteriosclerosis, hypertension, hyperthyroidism,Glaucoma,Agitated states,History of seizures or tics,Concomitant use of MAOIs or within 14 days of MAOI use
Hypersensitivity to amphetamine or other sympathomimetic amines,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation,Glaucoma,Hyperthyroidism,Moderate to severe hypertension,Advanced arteriosclerosis,Symptomatic cardiovascular disease,History of drug abuse
Avoid high-fat meals as they may delay absorption. Limit caffeine intake (coffee, tea, colas) as it may increase stimulant effects and risk of side effects. Acidic foods/juices (e.g., orange juice, grapefruit juice) can decrease absorption; take medication with water. Maintain adequate hydration.
Avoid high-fat meals as they may delay absorption. Avoid excessive caffeine intake as it may potentiate stimulant effects and increase anxiety. Ensure adequate hydration to reduce the risk of dry mouth and constipation. No specific foods are contraindicated, but a balanced diet is recommended to mitigate appetite suppression.
First trimester: Possible increased risk of congenital malformations (e.g., heart defects, oral clefts) based on limited human data; animal studies show fetal abnormalities. Second and third trimesters: Risk of prematurity, low birth weight, and neonatal withdrawal symptoms (e.g., irritability, poor feeding). Amphetamines may cause vasoconstriction leading to placental insufficiency.
Pregnancy category C. First trimester: possible increased risk of congenital malformations (e.g., cardiac, orofacial clefts) based on limited human data and animal studies. Second and third trimesters: risk of fetal growth restriction, preterm delivery, and neonatal withdrawal symptoms (including irritability, hyperexcitability). Use only if potential benefit justifies risk.
Biphetamine is excreted into breast milk. M/P ratio is approximately 2.5–7.5. Use is contraindicated during breastfeeding due to potential for adverse effects on infant development (e.g., irritability, poor weight gain).
Not recommended. Amphetamine is excreted into breast milk; M/P ratio not established. Potential for infant exposure causing adverse effects such as irritability, poor feeding, and sleep disturbance. American Academy of Pediatrics recommends contraindication.
No established guidelines; avoid use in pregnancy. If unavoidable, use lowest effective dose with careful monitoring. Increased clearance may necessitate higher doses, but risks outweigh benefits.
No established dosing guidelines. Pregnancy may alter pharmacokinetics of amphetamines due to increased plasma volume and hepatic metabolism; consider using the lowest effective dose. Monitor clinical response and adjust as needed.
Biphetamine 12.5 is a mixed amphetamine salt product (D-amphetamine and L-amphetamine). Monitor for cardiovascular events, especially in patients with pre-existing conditions. Avoid use within 14 days of MAOIs. Use with caution in patients with hypertension, hyperthyroidism, glaucoma, or history of drug abuse. Assess for tics or Tourette's syndrome. Monitor growth in pediatric patients. May cause withdrawal symptoms upon abrupt discontinuation.
Biphetamine 7.5 is a fixed-dose combination of amphetamine and dextroamphetamine (ratio 1:1) used for ADHD. Monitor for cardiovascular adverse effects including hypertension, tachycardia, and sudden cardiac death, especially in patients with structural cardiac abnormalities. Avoid in patients with a history of drug abuse due to high abuse potential. Use with caution in patients with bipolar disorder as it may induce manic episodes. Assess for growth suppression in pediatric patients during long-term therapy.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid taking late in the day to prevent insomnia.,Report any chest pain, shortness of breath, or fainting immediately.,May cause dizziness or blurred vision; avoid driving until you know how the medication affects you.,Do not stop abruptly; your doctor will taper the dose to avoid withdrawal symptoms.,Inform your doctor if you have a history of heart problems, high blood pressure, seizures, or mental health conditions.,Avoid alcohol and other CNS stimulants.,Store at room temperature away from moisture and heat.
Take the medication exactly as prescribed; do not increase the dose or frequency without consulting your doctor.,Avoid taking this medication late in the day to prevent sleep disturbances.,Report any chest pain, shortness of breath, or fainting immediately.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.,Store in a secure location away from children and others to prevent misuse.,Attend regular follow-ups for blood pressure, heart rate, and growth monitoring (in children).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BIPHETAMINE 12.5 vs BIPHETAMINE 7.5, answered by our medical review team.
BIPHETAMINE 12.5 is a Central Nervous System Stimulant that works by Biphetamine 12.5 is a central nervous system stimulant that increases the levels of norepinephrine and dopamine in the synaptic cleft by inhibiting the reuptake of these neurotransmitters and by promoting their release from presynaptic terminals.. BIPHETAMINE 7.5 is a Central Nervous System Stimulant that works by Biphetamine 7.5 is a combination of amphetamine enantiomers (dextroamphetamine and levoamphetamine) that increase synaptic concentrations of dopamine and norepinephrine by inhibiting presynaptic reuptake and promoting release into the synaptic cleft.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BIPHETAMINE 12.5 and BIPHETAMINE 7.5 depend on the specific clinical indication. These are both Central Nervous System Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BIPHETAMINE 12.5 is: 12.5 mg orally once daily in the morning, may titrate weekly by 12.5 mg to maximum 75 mg/day.. The standard adult dose of BIPHETAMINE 7.5 is: Initial 7.5 mg orally once daily in the morning, titrated based on response and tolerability. Maximum daily dose is 30 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BIPHETAMINE 12.5 and BIPHETAMINE 7.5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BIPHETAMINE 12.5 is classified as Category C. First trimester: Possible increased risk of congenital malformations (e.g., heart defects, oral clefts) based on limited human data; animal studies show fetal abnormalities. Second. BIPHETAMINE 7.5 is classified as Category C. Pregnancy category C. First trimester: possible increased risk of congenital malformations (e.g., cardiac, orofacial clefts) based on limited human data and animal studies. Second . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.